ArticleAACE endocrinology and diabetes
Insulin Resistance Among Patients With Multiple Endocrine Neoplasia Type 1: A Systemic Review and Meta-Analysis.
Article in AACE endocrinology and diabetes. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Objective: Multiple endocrine neoplasia type 1 (MEN1) is a hereditary syndrome characterized by predisposition to tumors of parathyroid, pituitary, and enteropancreatic cells. Multiple studies previously showed increased prevalence of insulin resistance and incidence of cardiovascular diseases, decreased life expectancy in patients with MEN1. In this meta-analysis, we aim to further evaluate the extent of insulin resistance among individuals with MEN1. Methods: We systematically searched PubMed, Embase, Scopus, Web of Science Core Collection, and the Cochrane Central Register of Controlled Trials (CENTRAL). Studies involving at least 5 patients with MEN1 and reporting on insulin resistance were included. Primary outcome designated as prevalence of insulin resistance. Meta-analyses done and odds ratios were calculated via the random effects model. Results: Out of 1453 studies, 5 met the inclusion criteria, involving 606 patients with MEN1 and 4431 controls were included in the meta-analysis. Patients with MEN1 had a significantly higher prevalence of insulin resistance with an odds ratio of 5.58 (95% confidence interval [4.02, 7.74]. No heterogeneity was observed (Tau Conclusions: To our best knowledge, this represents the first meta-analysis on MEN1 and insulin resistance. We have identified a higher prevalence of insulin resistance among individuals with MEN1 compared to controls, independent of age, sex, or body mass index. Given these findings, we recommend that patients with MEN1 should be screened early in the disease course for impaired glucose tolerance, as this may help prevent future cardiovascular events and enhance life expectancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.